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Purpose or Objective  
Intensity modulated radiation therapy (IMRT) as a 
treatment technique has become the standard of care in 
treatment of nasopharyngeal carcinoma. The dosimetry of 
the modality with respect to parotid and other normal 
organ sparing and other clinical outcomes are presented 
in our study. 
Material and Methods  
The medical records of 32 patients with histologically 
proven primary nasopharygeal carcinoma treated with 
IMRT were retrospectively reviewed. The majority of 
patients showed advanced clinical staging. IMRT was 
performed in step-and-shoot technique using an 
integrated boost concept. The boost volume covered the 
primary tumor and involved nodes with doses of 66–70.4 
Gy (single dose 2.2 Gy) and uninvolved regional nodal 
areas were covered with doses of 54–59.4 Gy (median 
single dose 1.8 Gy). The dose constratints were optimized 
and normal organs at risk (OARs) spared. Dosimetric 
analysis was done and quality of life was assessed at initial 
stage and later during follow up at 3 and 6 months. The 
survival analysis was evaluated. 
Results  
The median follow-up for the entire cohort was 24 months. 
Radiation therapy was completed without interruption in 
all patients. Four local recurrences have been observed, 
transferring into 1-, 3-, and 5-year Local Control (LC) rates 
of 95%, 90% and 90%. Two patients developed regional 
nodal recurrence, resulting in 1-, 3-, and 5-year Regional 
Control (RC) rates of 95%. All locoregional failures were 
located inside the radiation fields. Distant metastases 
were found in three patients, transferring into 1-, 3, and 
5-year Distant Control (DC) rates of 90%, 84% and 82%. 
Progression free survival (PFS) rates after 1, 3 and 5 years 
were 85%, 72% and 65% and 1-, 3- and 5-year Overall 
Survival (OS) rates were 90%, 85% and 80%. Acute and 
chronic toxicities were assessed as per EORTC grading 
scale and found to be better with IMRT and under 
acceptable tolerance levels. 
Conclusion  
IMRT with an integrated boost concept yielded good 
disease control, good OARs sparing, better quality of life 
outcomes and overall survival in patients suffering from 
primary nasopharyngeal cancer with acceptable acute side 
effects and limited rates of late toxicity. 
  
PO-092 Dosimetric comparaison of conformal and 
intensity modulated radiotherapy for locally recurrent 
NPC 
W. Mnejja1, L. Farhat1, H. Daoud1, T. Sahnoun1, N. 
Fourati1, W. Siala1, J. Daoud1 
1Hopital Habib Bourguiba, radiotherapy, Sfax, Tunisia 
 
Purpose or Objective  
Locally recurent nasopharyngeal carcinoma (NPC) can be 
salvaged by reirradiation with a substantial degree of 
radiation   related   complications. 
The aim of this study was to evaluate the dosimetric 
advantage of intensity modulated radiotherapy (IMRT) in 
treating locally recurrent NPC. 
Material and Methods  
Between January 2014 and september 2016, six patients 
with no metastatic locally recurrent NPC were re-
irradiated with concomitant chemotherapy. The median 
prescrepted dose was 60 Gy with 2 Gy per fraction. 
Treatment planning of each patient was performed for 
tow techniques : Three dimentional Conformal 
radiotherapy (3D CRT) and Intensity modulated 
radiotherapy (IMRT). The minimum dose (Dmin), the 
maximuim dose (Dmax) and the volume that received 95% 
of the dose prescrepted (D95%) of the planning target 
volume (PTV) and doses to the organs at risk (Spinal cord 
and brainstem) were calculated and compared for the tow 
techniques.   
Results  
All two techniques delivered adequate doses to the PTV. 
The average Dmin was 48Gy for the two techniques, the 
average Dmax was 67,5 Gy vs 64,2 Gy respectively for IMRT 
and 3D CRT (p=0,41) and D95% was 96%. Concerning the 
organs at risk, the Dmax for the brainstem was 
significantly higher for 3D CRT (22 Gy vs 14 Gy, p= 0,003). 
This finding were similar for the spinal cord (20Gy vs 7,8 
Gy). But, the difference was not statically significant 
(p=0,12). 
Conclusion  
Based on the dosimetric comparaison, IMRT was optimal 
by delivering a conformal and homogenous dose to the PTV 
with significant better sparing of critical organs than 3D 
CRT. 
In this regard, re-irradiation using IMRT may be a very 
attractive technique for locally recurrent NPC.     
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Purpose or Objective  
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30-50% of patients receiving post-operative radiotherapy 
(RT) for parotid cancer experience ipsilateral hearing loss. 
IMRT can reduce radiation dose to the cochlea. COSTAR 
(CRUK/08/004) investigated the role of IMRT in reducing 
hearing loss in these patients. 
Material and Methods  
Patients with histologically confirmed carcinoma of the 
parotid gland (pT1-4, pN0-3, M0) were randomized 1:1 to 
receive CT-planned 3-D Conformal RT (3DCRT) or Cochlea 
Sparing-IMRT (CS-IMRT). 60Gy (R0 resection) or 65Gy (R1-
2) in 30 fractions were delivered over 6 weeks. Treatment 
allocation used minimisation, balancing for centre and 
planned RT dose. The primary endpoint was proportion of 
patients with hearing loss in the ipsilateral cochlea of 
10dB measured by bone conduction at 4000Hz 12 months 
(m) after RT; compared between randomized groups by an 
exact test (
=0.05). Secondary endpoints (
=0.01) 
included hearing loss at 6 and 24m, vestibular function, 
acute and late toxicity, patient reported quality of life 
(including Glasgow Hearing Aid Benefit Profile (GHABP), 
time to tumour recurrence and survival.  
Results  
110 patients (54 3DCRT; 56 CS-IMRT) were randomised 
between 2008 and 2013 from 22 UK centres. 99 (90%) 
patients were R1-2 (47 3DCRT; 52 CS-IMRT). Mean dose to 
the ipsilateral cochlea was 56.2Gy for 3DCRT and 35.7Gy 
for CS-IMRT, (p<0.001). 66/110 (60%) patients were 
evaluable for the primary endpoint; the main reasons for 
non-evaluability were non-attendance at follow-up 
audiology and bone conduction assessment not performed. 
At 12m, a loss of 10dB in ipsilateral bone conduction was 
observed in 14/35 (40%) 3DCRT and 11/31 (36%) CS-IMRT 
patients (p=0.80). No statistically significant differences 
in bone or air conduction were observed at 6m or 24m 
after RT nor for any GHABP initial disability or handicap 
subscales, vestibular function, acute or late toxicity, 
overall quality of life, time to tumour recurrence or 
survival. 
Conclusion  
IMRT reduced the radiation dose below the accepted 
tolerance of the cochlea, but this did not lead to a 
statistically significant reduction in the proportion of 
patients with hearing loss in the ipsilateral ear at 12 
months after RT.  
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Purpose or Objective  
To evaluate radiation induced volume changes in the 
parotid glands and submandibular glands in patients with 
head and neck cancer receiving Intensity Modulated 
Radiotherapy (IMRT) and correlation with the mean doses 
received by the glands and assessment of timings of the 
volume changes during fractionated RT. 
Material and Methods  
Fourty five patients of Head and Neck Cancers, satisfying 
the inclusion criteria were included from May 2015 to Dec 
2015 and were treated with radical or post-operative 
Radiotherapy using IMRT with or without Chemotherapy. 
Radiotherapy planning CT scans were done at pre RT, after 
40 Gy and on completion of treatment for each patient. 
Parotid and submandibular gland volumes were re 
contoured on each study scan and rechecked with same 
observer. The volumes (V0 - Volume on initial CT scan) and 
mean doses to the parotid and submandibular glands were 
calculated from the Dose-volume histograms (DVHs) of the 
IMRT plan, done on pre RT scan. The re contoured volumes 
of parotid and submandibular glands on the CT after 40 Gy 
(V1) and on completion (V2) were noted. Volume changes 
of the glands were assessed and statistical analysis was 
done to see any correlation between the mean dose and 
volume changes of the glands. 
Results  
The total mean dose to the parotid glands in IMRT patients 
was 24.47 Gy (for the ipsilateral and contralateral parotid 
glands they were 41.61 Gy and 26.13 Gy, respectively). 
For IMRT patients, the total mean doses to spared and 
irradiated submandibular glands were 7.39 Gy and 58.04 
Gy, respectively. The average volume loss after 4 weeks 
of RT, upon completing RT versus before RT were 22.12%, 
31.12%, and between 4 th week to completion of RT 
11.56% for the parotid glands and 25.26%, 32.93% and 
between 4 th week to completion of RT 10.28% for the 
submandibular glands, respectively. The average mean 
volumes of both parotid glands and submandibular glands 
after 4 weeks of RT and upon completing RT were 
significantly smaller than before RT (P value <.001). We 
observed volume loss during RT in the parotid and the 
submandibular glands. The average rates of volume loss 
during the first 4 weeks of RT (22.12% and 25.26% 
respectively) were larger than in the last 2/3 weeks of RT 
(11.56% and 10.28% respectively). Volume loss at higher 
doses (>30 Gy) to the glands was significantly larger than 
at low doses (<30 Gy; P < .001). 
Conclusion  
The parotid and submandibular glands shrunk during RT. 
These gland volume reductions correlated significantly 
with the mean dose to the irradiated glands; the spared 
glands showed few changes. 
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Purpose or Objective  
Electrochemotherapy is a local tumour treatment 
currently used for cutaneous tumours and metastases in a 
palliative setting. Electric pulses are applied to the 
exterior of the cells creating a temporary permeability of 
the cell membrane. During this phase chemotherapy can 
gain access to the interior of the cell and cause apoptosis. 
Electrochemotherapy applied on mucosal tumours has only 
been tested in a few trials. The purpose of this trial was 
to evaluate electrochemotherapy on recurrent head and 
neck tumours in a palliative setting.  
Material and Methods  
ClinicalTrials.gov Identifier: NCT02549742. The study was 
designed as a phase II, clinical trial, with planned decision 
to discuss continuation after the first twelve evaluable 
patients. Patients included had recurrence of carcinoma 
in the oral cavity, rhino-, oro- or hypopharynx and no 
further curative treatment options left as determined by 
multidisciplinary conference (MDT). Electrochemotherapy 
